Australia's most trusted
source of pharma news
Monday, 02 February 2026
Posted 2 February 2026 AM
MSD has finally got its long-sought recommendation from the PBAC for a broad cancer listing for Keytruda and the more than 30 indications approved by the TGA.
At its December Intracycle Meeting the PBAC recommended a broad listing of Keytruda for the treatment of advanced or metastatic cancers, after MSD addressed the Committee's concerns from the July 2025 submission regarding access for patients with rare cancers, concerns which had left MSD 'bewildered'.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.